Method for detecting component of extracellular vesicle suitable for predicting muscle mass and strength reduction caused by chronic liver disease
The detection of specific microRNAs in blood extracellular vesicles addresses the lack of biomarkers for hepatic sarcopenia, enabling the prediction of muscle weakness and muscle mass changes in chronic liver disease patients.
Patent Information
- Application Number
- JP2023079304
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods lack biomarkers to differentiate between age-related sarcopenia and hepatic sarcopenia in patients with chronic liver disease, necessitating a need for blood-based markers to predict muscle weakness and muscle mass changes.
A method involving the detection of specific microRNAs (miRs) in blood extracellular vesicles, specifically miR-483, let-7i, miR-142, miR-4488, miR-1304, miR-20a, miR-378a, and miR-152, is used to evaluate the presence of sarcopenia associated with chronic liver disease by comparing their expression levels with healthy individuals.
The method allows for the detection of sarcopenia as a complication of chronic liver disease, providing a reliable biomarker for predicting muscle weakness and muscle mass changes.
Smart Images

Figure 2024163567000001 
Figure 2024163567000002 
Figure 2024163567000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for detecting components of extracellular vesicles in blood, which is useful for predicting muscle mass and muscle strength decline associated with chronic liver disease. [Background technology]
[0002] The liver is the central organ responsible for glucose and fat metabolism, and it is known that when patients suffer from severe liver disease, organ connectivity (liver-skeletal muscle) occurs, which can lead to complications in distant organs. As an example of such organ connectivity, it has been reported that in nonalcoholic steatohepatitis (NASH), the progression of liver fibrosis is correlated with sarcopenia, and that in multiple liver diseases, the survival rate is significantly reduced in those with sarcopenia. Sarcopenia is registered in the International Classification of Diseases, 10th Revision (ICD10), and research into the relationship between liver disease and sarcopenia is becoming increasingly important. However, this research has only just begun, and it is hoped that new humoral factors that connect the liver and skeletal muscle will be identified. Current technology cannot diagnose whether or not complications will occur from chronic liver disease, or predict which organs, such as skeletal muscle, brain, kidneys, or lungs, will develop complications.
[0003] In a previous study, the inventors demonstrated the possibility of predicting hepatic sarcopenia by detecting EV-microRNA (miR) as a component of extracellular vesicles (EVs, nanoparticles released from cells that also contain exosomes) in the blood of patients with chronic liver disease using a microRNA array. At present, there are no reports of predicting human hepatic sarcopenia using blood EV-miR. In addition, a study using aging mice has reported that an increase in EV-miR-690 is associated with a decrease in muscle mass (Non-Patent Document 1), but this study did not use human samples, and there have been no reports that the same EV-miR is associated with human hepatic sarcopenia. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Atrophic skeletal muscle fiber-derived small extracellular vesiclemiR-690 inhibits satellite cell differentiation during aging. Shao X, Gong W,Wang Q, Wang P, Shi T, Mahmut A, Qin J, Yao Y, Yan W, Chen D, Chen X, Jiang Q,Guo B. J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):3163-3180. [Non-Patent Document 2] Japan Society of Hepatology, Criteria for Determining Sarcopenia in Liver Disease (2nd Edition) <https: / / www.jsh.or.jp / lib / files / medical / guidelines / jsh_guidlines / sarcopenia_criterion_v2.pdf> Summary of the Invention [Problem to be solved by the invention]
[0005] Sarcopenia is classified into primary sarcopenia associated with aging and secondary sarcopenia associated with liver disease. Sarcopenia is currently diagnosed by measuring grip strength and skeletal muscle mass using CT or impedance analysis (Non-Patent Document 2). There are no biomarkers to predict sarcopenia. In Japan, the proportion of elderly people among patients with liver disease is extremely high, making it necessary to exclude primary causes. In addition, the aging of patients with liver disease is accelerating, and advances in treatment have extended life expectancies, further accelerating the aging of patients. Given this situation, there is a need for a blood biomarker that can distinguish between sarcopenia associated with aging and hepatic sarcopenia. The present invention has been made in view of the above problems, and its purpose is to provide a detection method useful for predicting sarcopenia associated with chronic liver disease. The final decision will be made by a licensed physician or other professional based on comprehensive knowledge including the data obtained by the present invention. [Means for solving the problem]
[0006] In order to solve the above problems, the inventors conducted intensive research and discovered that data on increases and decreases in specific miRNAs in blood samples collected from subjects with chronic liver disease can be used as an indicator for evaluating the worsening of sarcopenia, and have basically completed the present invention. Thus, the detection method of the present invention, which is characterized by obtaining one piece of data for evaluating whether or not chronic liver disease is accompanied by sarcopenia, is characterized by measuring at least one miR selected from the group consisting of eight microRNAs (miRs), namely miR-483, let-7i, miR-142, miR-4488, miR-1304, miR-20a, miR-378a, and miR-152, in blood extracellular vesicles (EVs) of a blood sample collected from a subject with chronic liver disease, and comparing the data obtained from a blood sample from a healthy individual.
[0007] A test kit according to another invention is a test kit capable of measuring gene expression of at least one or more miRs selected from the group consisting of eight microRNAs (miRs), namely, miR-483, let-7i, miR-142, miR-4488, miR-1304, miR-20a, miR-378a, and miR-152, in a blood sample collected from a subject having chronic liver disease, comprising: a binding agent that specifically binds to the miR; The device is characterized in that it includes a reagent for measuring the expression level of the miR, and provides one of the pieces of data for evaluating whether or not the chronic liver disease is accompanied by sarcopenia.
[0008] In the above invention, miR-483 is UCACUCCUCUCCUCCCGUCUU (SEQ ID NO: 1), let-7i is CUGGCUGAGGUAGUAGUUUGUGCUGUUGGUCGGGUUGUGACAUUGCCCGCUGUGGAGAUAACUGCGCAAGCUACUGCCUUGCUA (SEQ ID NO: 2), miR-142 is UGUAGUGUUUCCUACUUUAUGGA (SEQ ID NO: 3), miR-4488 is GGUAGGGGGCGGGCUCCGGCGCUGGGACCCCACUAGGGUGGCGCCUUGGCCCCGCCCCGCCC (SEQ ID NO: 4), and miR-1304 is AAACACUUGAGCCCAGCGGUUUGAGGCUACAGUGA GAUGUGAUCCUGCCACAUCUCACUGUAGCCUCGAACCCCUGGGCUCAAGUGAUUCA (SEQ ID NO: 5), miR-20a is UAAAGUGCUUAUAGUGCAGGUAG (SEQ ID NO: 6), miR-378a is AGGGCUCCUGACUCCAGGUCCUGUGUGUUACCUAGAAAUAGCACUGGACUUGGAGUCAGAAGGCCU (SEQ ID NO: 7), and miR-152 is a microRNA having the sequence UGUCCCCCCCGGCCCAGGUUCUGUGUGAUACACUCCGACUCGGGCUCUGGAGCAGUCAGUGCAUGACAGAACUUGGGCCCGGAAGGACC (SEQ ID NO: 8).
[0009] In the present invention, chronic liver disease means a disease in which inflammation in the liver continues for more than six months, and specific examples include viral hepatitis, cirrhosis of the liver, fatty liver, alcohol-related liver disease, autoimmune hepatitis, and liver cancer. A blood sample refers to whole blood, serum, plasma, etc., taken from a subject. "miR" refers to small non-coding RNA found in animals and plants. In humans, miRs consist of about 22 nucleotides and function in the transcriptional and post-transcriptional regulation of gene expression. miRs are encoded in the nuclear DNA of eukaryotic cells and function through base pairing with complementary sequences in mRNA molecules, resulting in gene silencing through transcriptional repression or targeted degradation.
[0010] Methods for measuring miR can be determined by conventional methods well known in the art, such as immunoassays (e.g., ELISA), molecular or biochemical assays (quantitative PCR, colorimetric assays), analytical methods (e.g., mass spectrometry), and sequencing. Alternatively, total RNA can be measured from blood samples. An appropriate internal control, such as a miR of known sequence and amount (e.g., miR-39 in C. elegans), can be added to the sample prior to RNA extraction. Quantitative PCR is used to determine Cq values. External detection laboratories can be used to perform such assays, or commercially available kits can be used. An example of an external detection agency is Craif Corporation. Commercially available kits, such as Taqman miRNA qRT-PCR Assay: Taqman microRNA Reverse Transcription Kit, TaqMan microRNA Assay 20x, and TaqMan Universal Master Mix II (Applied Biosystems), can be used according to the manufacturer's instructions. Reverse transcription reactions can be performed using commercially available PCR systems, such as the GeneAmp PCR System 9700 Thermal Cycler (Applied Biosystems), with appropriate cycling parameters (e.g., 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes, followed by a hold at 4°C). Reverse transcription reactions can also be performed in a multiplex format.
[0011] Then, quantitative PCR reaction is carried out using a quantitative PCR system such as a CFX96 real-time system (C1000Touch thermal cycler: Bio-Rad). Cycling conditions include, for example, 95°C for 10 minutes, followed by 50 cycles of 95°C for 15 seconds and 60°C for 60 seconds, followed by reaction at 30°C for 30 seconds. The "binding agent" used in the test kit means an agent that recognizes and binds to the target miR, and for example, a DNA probe having a sequence complementary to the target miR can be used. In this case, the DNA probe can be labeled with biotin (biotinylated DNA probe). When an ELISA system is used, for example, the "reagent to be measured" includes an antibody that specifically recognizes the miR / DNA hybrid chain, a color-developing enzyme (an avidinylating enzyme (e.g., horseradish peroxidase (HRP)) and a color-developing substrate (e.g., TMB (3,3',5,5'-tetramethylbenzidine), PNPP (p-nitrophenyl phosphate disodium salt), ABTS (2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt), OPD (o-phenylenediamine dihydrochloride), etc.). Other commercially available products that can detect and measure miRs (e.g., Mir-X miRNA qRT-PCR TB Green Kit, microRNA Enzyme Immunoassay Kit (miREIA), TaqMan miRNA assays, TaqMan miRNA array cards, and TaqMan miRNA OpenArray panels) can be used.
[0012] When using the ELISA system, the target miR can be measured by the following procedure. A blood sample that may contain the target miR is hybridized with a biotinylated DNA probe. Meanwhile, an antibody that specifically recognizes the miR / DNA hybrid chain is coated in the wells of a microplate. A sample that may contain the miR / DNA hybrid chain is dropped into the well, incubated for an appropriate period of time, and then the well is washed. A solution containing streptavidin-binding enzyme is added to the well, which binds to biotin and is washed. After that, the target miR can be measured by reacting with an appropriate substrate. Effect of the Invention
[0013] According to the present invention, a method for detecting one of the data for evaluating sarcopenia that may accompany chronic liver disease from a blood sample can be provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Next, embodiments of the present invention will be described with reference to the drawings. However, the technical scope of the present invention is not limited to these embodiments, and the present invention can be embodied in various forms without changing the gist of the invention. <Test methods and results> 1. Detection of EV-microRNA (miR) in serum miRs in hepatocyte-derived extracellular vesicles (HC-EVs) were analyzed as follows. To identify circulating EV-miRs in hepatic sarcopenia associated with chronic liver disease, circulating EVs were collected from 10 ul of serum from two groups of patients with chronic liver disease, one with sarcopenia and the other without sarcopenia (117 men and 32 women), and all miR components were detected by miR-sequencing. The following method was used to detect all miR components. 10μL of serum sample was spread on a 1cm x 1cm cellulose nanofiber sheet with a pipette, and the cellulose nanofiber sheet was then dried for 7 days. Note that in this test, 7 days was set as the drying period because it was necessary to coordinate with other tests, but depending on the drying conditions, a shorter period may not cause any problems. Next, the sheet was immersed and washed in 1 mL of PBS that had been treated with a 0.22 μm filter. For the washing procedure, PBS was stored in a petri dish, and the dried cellulose nanofiber sheet was sandwiched between tweezers and washed by gently shaking it from side to side. Next, the cellulose nanofiber sheet was immersed in 1.5 mL of Norgen's Lysis buffer for 5 minutes, and then vortexed for 10 seconds. 1 mL of the Lysis buffer was removed and purified using the Norgen kit to obtain 50 μL of microRNA solution. A library was prepared from this microRNA solution and analyzed using a sequencer.
[0015] 2.Statistical Analysis of EV-miR According to the sarcopenia assessment criteria of the Japan Society of Hepatology, grip strength measurements of ≥ 28 kg for men and ≥ 18 kg for women are considered to be “no sarcopenia.” In addition, among patients who meet the grip strength criteria (weak grip strength), muscle mass measurements using CT and dedicated software are > 42 cm for men. 2 / m 2 , Female>38cm 2 / m 2 Patients with a higher score than this standard are considered to have no sarcopenia, while those with a lower score than this standard are considered to have sarcopenia. 2 / m 2 , Female: 3.92cm 2 / m 2PMI was used in this study. Grip strength should be included in the criteria for sarcopenia, but in reality, there are facilities where it is difficult to measure grip strength, and PMI (muscle mass) alone is sometimes used instead. In addition, many reports have shown a correlation between a decrease in PMI and the pathology and severity of the disease, and PMI is an important clinical indicator in addition to sarcopenia. In light of the above circumstances, this study conducted an analysis in two categories: "with or without sarcopenia" and "normal or decreased PMI." As described below, there were 88 people without sarcopenia by the criterion of sarcopenia, but 42 people had normal PMI by the criterion of PMI, resulting in a large difference. Basically, statistical analysis was performed on two groups, and the sensitivity and specificity and beta coefficient (weighting) by logistic regression were calculated using AI analysis using EV-miRs that showed significant changes.
[0016] 1) Comparison of two groups based on "with or without sarcopenia" (145 people, 4 people without grip strength values were excluded) In serum samples from 145 subjects, 47 EV-miRs were significantly changed in the two groups, 88 with sarcopenia and 57 with sarcopenia. In the "with sarcopenia" group, 42 miRs, including miR-378a-3p, miR-30c-5p, and miR-30e-5p, were decreased, and five miRs (miR-1273c, miR-196a-5p, miR-6131, miR-6746-3p, miR-6813-5p) were increased. The sensitivity of statistical analysis was 0.63, and the specificity was 0.71. In serum samples obtained from 113 men, 37 EV-miRs were significantly changed in the two groups, 73 with sarcopenia and 40 with sarcopenia. Thirty-six miRs, including miR-378a-3p, miR-181a-5p, and miR-30c-5p, were decreased in the "sarcopenia" group, and one miR (miR-1273c) was increased. The sensitivity of statistical analysis was 0.05, and the specificity was 0.997. In serum samples obtained from 32 women, 15 with sarcopenia (n=15) and 1 with sarcopenia (n=1), 4 EV-miRs (let-7a-3p, miR-142-3p, miR-4488, miR-502-3p) were significantly decreased in the sarcopenic group. The sensitivity and specificity of statistical analysis were 0.85 and 0.59, respectively. Because there were more male patients and the overall profile was similar to the male profile, it was considered appropriate to examine the overall profile. The decreased sensitivity in men was thought to be due to the small number of patients with sarcopenia. Table 1 shows the results of weighting performed by AI analysis using logistic regression. EV-miRs with higher weighting values were extracted as more meaningful. EV-miRs with decreased levels in the presence of sarcopenia are shown in normal typeface, and those with increased levels are shown in bold typeface (hsa-mir-6131, hsa-mir-6813-5p, hsa-mir-1273c, hsa-mir-6746-3p, hsa-mir-1273c).
[0017] [Table 1]
[0018] 2) Comparison of two groups based on "normal vs. decreased PMI" (normal PMI: 42 people, decreased PMI: 107 people) In serum samples from 149 subjects, 118 EV-miRs were significantly changed in the two groups of PMI normal (42 subjects) and PMI decreased (107 subjects). In the "PMI decreased" group, 116 miRs were decreased, including miR-378a-3p, miR-181a-5p, miR-181d-5p, miR-30a-3p, miR-30b-5p, miR-30c-5p, miR-30d-5p, miR-30e-3p, and miR-30e-5p, and two miRs were increased, miR-574-5p and miR-598-5p. The sensitivity of statistical analysis was 0.91, and the specificity was 0.37. In serum samples obtained from 117 men, 136 EV-miRs were significantly changed in the two groups of PMI normal (33 men) and PMI decreased (84 men). In the "PMI decreased" group, 134 miRs were decreased, including miR-378a-3p, miR-181a-5p, miR-30a-3p, miR-30a-5p, miR-30b-3p, miR-30c-5p, miR-30d-5p, miR-30e-3p, and miR-30e-5p, and two miRs were increased, miR-574-5p and miR-598-5p. The sensitivity of statistical analysis was 0.92, and the specificity was 0.33. In serum samples obtained from 32 women, 13 EV-miRs were significantly changed in the two groups, PMI normal (n=9) and PMI decreased (n=23). Ten miRs, including miR-4488, were decreased in the "PMI decreased" group, while three miRs, miR-1290, miR-15a-5p, and miR-9985, were increased. The sensitivity of statistical analysis was 0.93, and the specificity was 0.38. Since there were many male patients, and the overall profile was similar to the male profile, it was considered appropriate to examine the overall profile. The decrease in specificity was thought to be due to the small number of people with normal PMI. The results of weighting performed by logistic regression analysis using AI analysis are shown in Table 2. EV-miRs with higher weighting values were extracted as more meaningful. Those that decreased due to PMI decrease are shown in normal font, and those that increased are shown in bold (hsa-mir-574-5p, hsa-mir-598-5p, hsa-mir-574-5p, hsa-mir-598-5p,hsa-mir-1290, hsa-mir-15a-5p, hsa-mir-9985).
[0019] [Table 2]
[0020] Since there were EV-miRs that matched in the analyses of 1) and 2) above, common EV-miRs in the overall profiles of sarcopenia and PMI were extracted by AI analysis, and 13 miRs were common, as shown in the four columns on the left of Table 3. When the same analysis was performed for men and women, as shown in the right column of Table 3, 10 miRs were common between sarcopenia and PMI in men and 1 miR was common in women. By combining these profiles, eight EV-miRs were identified that can evaluate hepatic sarcopenia as a complication of chronic liver disease: miR-483-3p, let-7i-3p, miR-142-3p, miR-4488, miR-1304-3p, miR-20a-5p, miR-378a-3p, and miR-152-3p.
[0021] [Table 3]
[0022] After considering everything together, the following EV-miRs were considered to be useful for hepatic sarcopenia. 1) Three miRs were identified in a previous analysis by the inventors using a different method and were also detected in this study: miR-378, miR-181, and miR-30. 2) The six miRs that were elevated in patients with sarcopenia or decreased PMI were miR-574-5p, miR-598-5p, miR-1273c, miR-6131, miR-6813-5p, and miR-6746-3p. 3) Eight miRs were detected in both the sarcopenia and PMI criteria: miR-483-3p, let-7i-3p, miR-142-3p, miR-4488, miR-1304-3p, miR-20a-5p, miR-378a-3p, and miR-152-3p.
[0023] Thus, according to this embodiment, a method for detecting one of the data for evaluating sarcopenia as a complication of chronic liver disease from a blood sample can be provided.
Claims
1. A detection method characterized by measuring at least one miR selected from the group consisting of eight microRNAs (miRs), namely miR-483, let-7i, miR-142, miR-4488, miR-1304, miR-20a, miR-378a, and miR-152, in extracellular vesicles (EVs) from a blood sample collected from a subject with chronic liver disease, and comparing the measured miR with data obtained from a blood sample from a healthy individual to obtain one piece of data for evaluating whether or not chronic liver disease is accompanied by sarcopenia.
2. A test kit capable of measuring gene expression of at least one or more miRs selected from the group consisting of eight microRNAs (miRs), namely, miR-483, let-7i, miR-142, miR-4488, miR-1304, miR-20a, miR-378a, and miR-152, in a blood sample collected from a subject having chronic liver disease, comprising: a binding agent that specifically binds to the miR; A test kit comprising a reagent for measuring the expression level of the miR, and characterized by obtaining one of the pieces of data for evaluating whether or not the chronic liver disease is accompanied by sarcopenia.
